Table 1b.

The clinicopathological features of all cases in the control group

Case no	Age	Tumor localization	Tumor size (cm)	FNA site	HG	NG	Axillary lymph nodes	Excision type	Tumor type	ER	PR	cerbB2 (score)	Ki67 (%)	Molecular subtype
1	77	right	6	lymph node	3	3	11/21	MRM	IDC	90% +++	10% ++	2 (SISH -)	38	luminal B
2	69	left	3	lymph node	2	2	13/13	MRM	IDC	60% ++	90% +++	1	20	luminal B
3	65	right	3,5	lymph node	3	3	5/21	BCS + axilla	IDC	100% +++	70% +++	0	40	luminal B
4	57	left	2,5	lymph node	2	2	24/24	BCS + axilla	IDC	100% +++	70% ++	0	18	luminal B
5	48	left	1,8	breast	2	2	0/1	BCS + SLNB	IDC	85% +++	70% +++	0	10	luminal A
6	64	right	2,8	breast	2	2	4/13	BCS + axilla	IDC	100% +++	5% +++	0	20	luminal B
7	72	left	1,4	breast	2	2	0/2	BCS + SLNB	IDC + mucinous ca	100% +++	100% +++	0	22	luminal B
8	40	left	1,5	breast	2	2	0/2	BCS + SLNB	IDC	100% +++	100% +++	1	48	luminal B
9	43	right	1,5	lymph node	2	2	3/22	mastectomy + axilla	IDC	100% +++	95% +++	2 (SISH -)	33	luminal B
10	54	right	3,6	lymph node	3	3	4/8	BCS + SLNB	IDC	100% +++	10% +++	0	80	luminal B
11	62	right	1,8	lymph node	2	2	4/21	mastectomy + axilla	IDC	98% +++	98% +++	0	22	luminal B
12	41	left	2	lymph node	2	2	2/13	MRM	IDC	100% +++	90% +++	0	28	luminal B
13	73	left	3,2	lymph node	2	2	4/7	BCS + axilla	IDC	100% +++	25% ++	0	15	luminal B
14	52	right	2,3	lymph node	1	2	1/15	mastectomy + axilla	IDC	95% +++	5% ++	1	25	luminal B
15	84	right	2,5	lymph node	3	2	2/6	MRM	IDC	negative	negative	1	80	triple negative